Transplantation results in two groups of patients:
From all patients, Just 5 people faced with GvHD. 2 of them were in the
MSC + HSC group and 3 in the control or HSC group alone. The incidence
of GVHD in the MCC receiving group was 104.5±21.90 days post
transplantation and in the control group was 35.66±10.69 days.
The mean WBC grafting time in the MSCs + HSCs group was 10.6±2.70 days
and in the non-recipient roup was 9.4±0.89 days (p-value=0.39) and No
significant difference was observed. And also there was no significant
difference in platelet engraftment time between two groups. Platelet
engraftment was 12.6±3.78 in HSC + MSC group and 11±2.54 in HSCs group
(p-value = 0.45). WBC engraftment was defined as a first day of three
consecutive days where the WBC was greater than
1000×103 / L and platelet engraftment was defined as a
first day of three consecutive days when platelet counts were obtained
without platelet count of 2000×103 / L. There was no
significant difference in the incidence of GVHD in the two groups of
patients (2 patients with grade 1 and 4 GvHD in MSC recipient group and
3 patients in control group). However, the duration of transplantation
until the onset of GVHD in the MSC + HSC recipient group was longer than
that of the HSC recipient group (104.5±21.90 vs 35.66±10.69).
According to Table 3, the mean age in MSC recipient group was 27.80±8.49
and in another one was 36 ± 12.76. The average GVHD initiation time for
MSC recipient group was 104.5±21.90 and in another group was
35.66±10.69. The average time for Plt engraftment in MSC recipient group
was 12.6±3.78 and in another group was 11±2.54. The mean time for WBC
engraftment for MSC recipient group was 10.6±2.70 and in the control
group was 9.4±0.89.
According to Table 4, there was a significant difference in the average
GVHD initiation time (day) between MSC + HSC group and HSC group alone
(P-Value = 0.01), on the other hand, the average time of Plt engraftment
and WBC engraftment were not significantly different between the two
groups according to their p-value of 0.45 and 0.39, respectively.
However, injections of MSCs in patients have been shown to prolong the
duration of transplantation day until the occurrence of GvHD and
generally decrease the severity of GvHD in these patients, but, the
small number of patients in this study did not yield accurate
conclusions.